Stockscreener 앱 받기
7.30
2.96%
0.21
시간 외 거래:
7.24
-0.06
-0.82%
전일 마감가:
$7.09
열려 있는:
$7.04
하루 거래량:
28,250
Relative Volume:
0.32
시가총액:
$53.26M
수익:
-
순이익/손실:
$-101.87M
주가수익비율:
-6.3478
EPS:
-1.15
순현금흐름:
$-83.46M
1주 성능:
-2.72%
1개월 성능:
-8.46%
6개월 성능:
-14.86%
1년 성능:
-13.56%
1일 변동 폭
$7.01
$7.30
1주일 범위
$6.85
$8.45
52주 변동 폭
$5.202
$11.35
Kezar Life Sciences Inc Stock (KZR) Company Profile
명칭
Kezar Life Sciences Inc
전화
650-822-5600
주소
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-03-16 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2018-07-16 | 개시 | Jefferies | Buy |
| 2018-07-16 | 개시 | Wells Fargo | Outperform |
| 2018-07-16 | 개시 | William Blair | Outperform |
Kezar Life Sciences Inc 주식(KZR)의 최신 뉴스
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR) - Business Wire
Kezar Life Sciences stock hits 52-week high at $7.5 By Investing.com - Investing.com South Africa
Kezar Life Sciences (NASDAQ:KZR) Shares Gap DownHere's What Happened - MarketBeat
Kezar Life Sciences announces 1-for-10 reverse stock split - MSN
Kezar Life Sciences stock hits 52-week high at $7.5 - Investing.com
Kezar Life Sciences announces 1-for-10 reverse stock split By Investing.com - Investing.com Canada
Kezar Life Sciences Stock Scheduled to Reverse Split on Wednesday, October 30th (NASDAQ:KZR) - MarketBeat
Kezar Life Sciences to Implement 1-for-10 Reverse Stock Split - Marketscreener.com
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split - BioSpace
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split | KZR Stock News - StockTitan
What Makes Kezar Life Sciences (KZR) a New Buy Stock - MSN
Kezar shares unchanged as takeover bid rejected By Investing.com - Investing.com UK
Kezar Life Sciences discontinues lupus nephritis programme after fatalities - Clinical Trials Arena
Kezar rejects Concentra's acquisition offer, adopts rights plan By Investing.com - Investing.com South Africa
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update - BioSpace
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study - Benzinga
Kezar stock falls 11% after board rejects Concentra offer (NASDAQ:KZR) - Seeking Alpha
Kezar discontinues development of zetomipzomib for lupus nephritis (NASDAQ:KZR) - Seeking Alpha
Kezar to discontinue mid-stage trial for lupus treatment - Reuters
Kezar rejects Concentra's acquisition offer, adopts rights plan - Investing.com
Kezar to focus on AIH drug after halting lupus trial - Investing.com
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan - StockTitan
Concentra Biosciences, LLC cancelled the acquisition of Kezar Life Sciences, Inc. from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others. - Marketscreener.com
Short Interest in Kezar Life Sciences, Inc. (NASDAQ:KZR) Increases By 13.6% - MarketBeat
Kezar Life Sciences, Inc. (NASDAQ:KZR) Sees Significant Growth in Short Interest - Defense World
Kezar Life Sciences (NASDAQ:KZR) Given "Neutral" Rating at HC Wainwright - MarketBeat
H.C. Wainwright maintains Neutral rating on Kezar shares amid acquisition bid - Investing.com UK
Concentra Biosciences proposes to buy Kezar Life Sciences - Investing.com India
Concentra Biosciences proposes to buy Kezar Life Sciences By Investing.com - Investing.com Australia
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal - BioSpace
Concentra boss eyes up struggling Kezar - The Pharma Letter
Analyzing Kezar Life Sciences Inc (KZR) After Recent Trading Activity - Knox Daily
Mackenzie Financial Corp Invests $35,000 in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
Concentra Biosciences, LLC submitted a non-binding proposal to acquire Kezar Life Sciences, Inc. from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others for $80.3 million. - Marketscreener.com
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Kezar Life Sciences Inc - Yahoo Finance
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Kezar Life Sci - GuruFocus.com
After-hours movers: Astera Labs, Saratoga Investment, Kezar Life Sciences, and more By Investing.com - Investing.com Canada
A new trading data show Kezar Life Sciences Inc (KZR) is showing positive returns. - SETE News
Post-Trade Analysis: Kezar Life Sciences Inc (KZR) Slides -2.95, Closing at 0.77 - The Dwinnex
What is the investor’s view on Kezar Life Sciences Inc (KZR)? - US Post News
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths - AOL
Polymyositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas - The Globe and Mail
US FDA puts hold on lupus trial after patient deaths - The Pharma Letter
FDA places hold on Kezar Life Sciences’ trial for lupus nephritis treatment - Clinical Trials Arena
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis - BioSpace
FDA places clinical hold on Kezar lupus drug after deaths - Investing.com India
US FDA puts Kezar Life Sciences' lupus treatment trial on hold after patient deaths - Reuters.com
Kezar zetomipzomib IND for lupus placed on FDA clinical hold (NASDAQ:KZR) - Seeking Alpha
FDA places clinical hold on Kezar lupus drug after deaths By Investing.com - Investing.com South Africa
US FDA puts clinical hold on Kezar Life Sciences' lupus treatment trial - Marketscreener.com
Kezar Life Sciences Inc (KZR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):